Septerna, Inc. is a clinical-stage biotechnology company focused on the discovery and development of oral small molecule therapies targeting G protein-coupled receptors (GPCRs). The company utilizes its proprietary Native Complex Platform to isolate, purify, and reconstitute full-length GPCR proteins in functional ternary complexes, enabling structure-based drug design. Its wholly-owned pipeline is concentrated in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. Notable product candidates include SEP-479, an oral small molecule PTH1R agonist in Phase 1 clinical trials for the treatment of hypoparathyroidism. The company intends to expand its pipeline into additional areas such as neurology, women’s health, cardiovascular, and respiratory diseases.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage septerna.com
Sector Healthcare IR page septerna.com
Tags
gpcr, oral small molecules, endocrinology, immunology, inflammation, metabolic diseases, structure-based drug design, cryo-em, drug discovery, Native Complex Platform, SEP-479
Press page septerna.com/news_item

Metrics

Valuation  
Market cap $ 1.999B
Market cap (USD) $ 1.999B
P/E -32.93
PEG —
P/BV 4.67
P/S 20.76
P/OCF -26.10
P/FCF -25.76
Dividend yield —
Turnover / mcap —
Returns  
ROE -12.2%
ROI -17.3%
ROIC -18.1%
Profit margin -106.4%
Growth  
Revenue growing Yes
Profits growing No
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding Yes
Buying back stock No
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 35
Quality score -60.0%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022
Revenue 45.951M 1.075M 151K 0
Net profit -48.879M -71.798M 4.18M -27.676M
Free cash flow 109.671M -69.573M -41.601M -24.592M

Figure FY 2025 FY 2024 FY 2023 FY 2022
Share price 27.88 22.9 — —
Price performance 12m 0.22 — — —

Filed figures

Figure Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) 151,000 171,000 10.4M
↳ YoY growth +13.2% +5,956.1%
Lease liabilities (USD) 12.6M 25.5M 23.6M
Cash and deposits (USD) 88.5M 238M 121M
Right-of-use assets (USD) 12.5M 23.6M 21.5M
Cash flow detail
Operating cash flow (USD) -38.7M -67.5M 110M
Purchases of property, plant and equipment (USD) -2.88M -2.1M -518,000
Change in receivables (cash effect) (USD) -151,000 -20,000 -10.2M
Change in payables (cash effect) (USD) -653,000 723,000 6.6M
Income taxes paid (cash effect) (USD) -75,000 -232,000 0.00
Share-based compensation (USD) 1.62M 3.15M 8.48M
Operating cash flow before change in receivables (USD) -38.6M -67.5M 120M
Free cash flow (OCF - PPE - intangibles) (USD) -41.6M -69.6M 110M
Income detail
Research and development expense (USD) 36M 65.3M 97.6M
Total comprehensive income (USD) 4.18M -71.7M -48.3M
Comprehensive income to owners (USD) 4.18M -71.7M -48.3M
Reported Mar 27, 2025 Mar 27, 2025 Mar 9, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Phase 1 Clinical Trial for PTH1R Agonist SEP-479 Ongoing; SAD / MAD Data Expected in Q1 2027

Plans to Initiate Phase 1 Clinical Trial of Newly Selected Oral TSHR NAM Development Candidate SEP-204 in Q1 2027

Cash Position of $565.2 Million Expected to Support Operating Plans at Least into mid-2029

SOUTH SAN FRANCISCO, Calif. – November 09, 2026 – Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today highlighted pipeline progress and anticipated milestones and reported financial results for the third quarter ended September 30, 2026.

“We are building momentum across our portfolio, with an upcoming important clinical milestone for SEP-479, our oral PTH1R agonist for hypoparathyroidism, and the selection of SEP-204 as our oral TSHR NAM development candidate for Graves’ disease and thyroid eye disease,” said Jeffrey Finer, M.D., Ph.D., Chief Executive Officer and Co-founder of Septerna.

Skip to content

Overview

Release Details

Septerna Announces Selection of SEP-204 as Development Candidate for Graves' Disease and TED and Reports Preclinical Data at the 2026 American Thyroid Association Annual Meeting

11.04.26

PDF Version

Potent, selective TSHR NAM with pre-clinical activity demonstrated across biochemical, thyroid and ocular endpoints

Favorable PK profile anticipated to support once-daily oral dosing in humans

Phase 1 clinical trial initiation planned for the first quarter of 2027

SOUTH SAN FRANCISCO, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced the selection of SEP-204 as its potential first-in-class development candidate for the treatment of Graves’ disease and thyroid eye disease (TED) and reported initial preclinical data ahead of a poster presentation at the 2026 American Thyroid Association (ATA) Annual Meeting on November 5.

SEP-204 is a potent and selective oral small molecule thyroid-stimulating hormone receptor (TSHR) negative allosteric modulator (NAM). SEP-204 inhibited TSHR activation in Graves’ disease animal models and has pharmacokinetic properties to support once daily dosing. A Phase 1 trial in healthy volunteers is anticipated to initiate in the first quarter of 2027.

“Based on the pre-clinical data we have generated to date, we believe SEP-204 has the potential to change the treatment paradigm for Graves’ disease and TED, two serious autoimmune endocrine diseases that can profoundly affect patients’ health and quality of life,” said Rajiv Patni, chief medical officer of Septerna. “We look forward to working closely with disease experts and the patient community to advance SEP-204 into clinical development and build upon these promising preclinical findings with clinical results.”

Preclinical studies of SEP-204 demonstrated the following key findings:

  • Potent TSHR inhibition with desirable drug-like properties and a high level of selectivity over the closely related follicle-stimulating hormone receptor (FSHR) and luteinizing hormone receptor (LHR).

  • Inhibition of thyroid-stimulating antibody (TSAb) activation of TSHR in human thyrocyte cell assays.

  • In Graves’ disease animal models, findings included restoration of normal thyroid hormone T4 levels and reductions in thyroid enlargement and orbital proptosis.

  • Dose-dependent increases in TSH levels followed by decreases in thyroid hormone levels were observed across preclinical species.

  • Generally well tolerated in 28-day GLP toxicology studies in rats and dogs.

  • High oral bioavailability and low clearance across preclinical species, with a projected human half-life of approximately 20-40 hours, which is anticipated to support once-daily oral dosing in humans.

About SEP-204, Graves’ Disease and Thyroid Eye Disease

SEP-204 is an investigational oral small molecule thyroid-stimulating hormone receptor (TSHR) negative allosteric modulator (NAM) being developed as a potential disease-modifying treatment for Graves’ disease and thyroid eye disease (TED). It is designed to block the overactivation of TSHR caused by patients’ autoantibodies in thyroid cells and orbital fibroblasts and has the potential to address both conditions. Graves’ disease is an autoimmune condition in which antibodies activate TSHR, stimulating excess thyroid hormone production and causing hyperthyroidism. Some patients also develop TED, a serious, potentially vision-threatening autoimmune condition affecting tissues behind the eyes that can cause eye bulging, swelling, pain and blurred or double vision. Current standard-of-care treatments do not address the shared underlying cause of both Graves’ disease and TED.

About Septerna Septerna, Inc. is a clinical-stage biotechnology company with a world-class team of GPCR experts and drug developers advancing cutting-edge science to unlock the full potential of GPCR therapies for patients with significant unmet needs. The company’s proprietary Native Complex Platform® is designed to enable new approaches to GPCR drug discovery and has led to the development of a diverse pipeline of novel oral small molecule drug candidates. Septerna is advancing programs in endocrinology, immunology and inflammation, metabolic diseases and additional therapeutic areas, both independently and with partners. For more information, please visit www.septerna.com.

Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements about Septerna’s beliefs and expectations regarding: the potential translation of preclinical findings to clinical outcomes in patients; the potential of SEP-204 to be a first-in-class, disease-modifying treatment for Graves’ disease and TED; advancing SEP-204 into a Phase 1 clinical study and the timing thereof; SEP-204’s potential for once daily dosing; the potential of its proprietary Native Complex Platform®; and the scope of protection it is able to establish and maintain for intellectual property rights covering its Native Complex Platform® and its product candidates; among others. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “objective,” “ongoing,” “plan,” “predict,” “project,” “potential,” “should,” or “would,” or the negative of these terms, or other comparable terminology are intended to identify forward-looking statements, although not all forward looking statements contain these identifying words.

Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, risks associated with: SEP-204 successfully entering and advancing through clinical trials including uncertainties related to opening investigational new drug applications and obtaining other regulatory approvals; risks related to clinical development outcomes including unexpected safety or efficacy findings; the results of preclinical studies not being predictive of future clinical outcomes; risks related to the timing of initiating clinical studies; and the scope of protection Septerna is able to establish and maintain for intellectual property rights covering its Native Complex Platform® and its product candidates; among others. These and other risks and uncertainties are described in greater detail in the section entitled “Risk Factors” in Septerna’s Quarterly Report on Form 10-Q for the three months ended June 30, 2026, as well as any subsequent filings with the Securities and Exchange Commission. In addition, any forward-looking statements represent Septerna’s views only as of today and should not be relied upon as representing its views as of any subsequent date. Septerna explicitly disclaims any obligation to update any forward-looking statements subject to any obligations under applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.

Investor Contact: Renee Leck, THRUST [email protected]

Media Contact: Carly Scaduto, THRUST [email protected]

◼

Discover more

About Us

View

Pipeline

View

Platform

View

Pioneering a New Era of GPCR Drug Discovery

Get In Touch

250 East Grand Avenue South San Francisco, CA 94080 650-338-3533

General Inquiries:

[email protected]

Investors & Media:

[email protected]

© 2026 Septerna

Skip to content

Overview

Release Details

Septerna to Participate in Upcoming Investor Conferences

11.03.26

PDF Version

SOUTH SAN FRANCISCO, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced that management will participate in the following investor conferences before the end of 2026:

Guggenheim 3rd Annual Healthcare Innovation Conference – Boston Fireside chat on Tuesday, November 10, 2026, at 10:00 a.m. ET

Stifel 2026 Healthcare Conference – New York Fireside chat on Wednesday, November 11, 2026, at 1:20 p.m. ET

UBS Global Biopharma Conference – London Fireside chat on Monday, November 16, 2026, at 2:00 p.m. GMT

9th Annual Evercore Healthcare Conference – Miami Fireside chat on Tuesday, December 1, 2026, at 7:55 a.m. ET

A live webcast of each presentation will be available in the investors section of the company’s website at www.septerna.com. The webcasts will be archived for at least 30 days following the presentation.

About Septerna Septerna, Inc. is a clinical-stage biotechnology company with a world-class team of GPCR experts and drug developers advancing cutting-edge science to unlock the full potential of GPCR therapies for patients with significant unmet needs. The company’s proprietary Native Complex Platform® is designed to enable new approaches to GPCR drug discovery and has led to the development of a diverse pipeline of novel oral small molecule drug candidates. Septerna is advancing programs in endocrinology, immunology and inflammation, metabolic diseases and additional therapeutic areas, both independently and with partners. For more information, please visit www.septerna.com.

Investor Contact: Renee Leck, THRUST [email protected]

Media Contact: Carly Scaduto, THRUST [email protected]

◼

Discover more

About Us

View

Pipeline

View

Platform

View

Pioneering a New Era of GPCR Drug Discovery

Get In Touch

250 East Grand Avenue South San Francisco, CA 94080 650-338-3533

General Inquiries:

[email protected]

Investors & Media:

[email protected]

© 2026 Septerna

Prompts

Septerna, Inc. (ticker SEPN), listed in United States.

ETFs Holding Septerna, Inc.

ETF Weight in ETF Shares Market value As of
MMSC 0.69% 8,239 $ 343.319K Nov 16, 2026
AFSM 0.32% 11,144 $ 464.37K Nov 16, 2026
SQLV 0.18% 1,547 $ 51.809K Jun 30, 2026
SYZ 0.17% 3,405 $ 114.033K Jun 30, 2026
FSCC 0.16% 15,261 $ 582.207K Aug 31, 2026
VFMO 0.10% 48,264 $ 1.841M Aug 31, 2026
AVSC 0.09% 66,070 $ 2.753M Nov 16, 2026
RESM 0.04% 47 $ 1,574.03 Jun 30, 2026
WSGE 0.03% 478 $ 19.13K Nov 18, 2026
DFAS 0.00% 38,498 $ 1.612M Nov 12, 2026
MSSM 0.00% 630 $ 24.035K Aug 31, 2026
DFAU 0.00% 3,027 $ 126.71K Nov 12, 2026
DFAC 0.00% 18,589 $ 778.136K Nov 12, 2026
DCOR 0.00% 2,214 $ 92.678K Nov 12, 2026
DFUS 0.00% 322 $ 13.479K Nov 12, 2026
AVSU 0.00% 28 $ 1,166.76 Nov 16, 2026
AVUQ 0.00% 90 $ 3,750.30 Nov 16, 2026